Advertisement

Advertisement
Solid Tumors
Immunotherapy

FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow

On November 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (Danyelza) in combination...

 

Breast Cancer

No Reduction in Recurrence Risk With Perioperative Aromatase Inhibitor Therapy in Postmenopausal Patients With HR-Positive Breast Cancer

As reported in The Lancet Oncology by Ian E. Smith, MD, and colleagues, the phase III POETIC trial found that perioperative aromatase inhibitor therapy...

 

Issues in Oncology

Case Series Study Explores Experiences of Transgender Patients With Cancer

In a retrospective case series reported in JAMA Oncology, Burns et al described clinical characteristics, treatment, experiences, and outcomes...

 


Advertisement
Skin Cancer
Immunotherapy

Machine Learning Algorithms May Help Predict Response to Immunotherapy in Patients With Advanced Melanoma

A study investigating a computational method that integrates deep learning on histology specimens with clinicodemographic variables...

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Symptom Management

Anne M. Barry-Weers, RN, on Decreasing Hospitalizations for Patients Receiving IV Chemotherapy

Hepatobiliary Cancer

ESMO Asia 2020: Futibatinib for Patients With Refractory Intrahepatic Cholangiocarcinoma and FGFR2 Fusions/Rearrangements

Clinical benefit was provided by the FGFR1–4 inhibitor futibatinib in patients with refractory intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements, including those enrolled in Asian countries. These findings were presented by Furuse et al at the ESMO Asia Virtual...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Lung Cancer

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage IB–IIIA EGFR Mutation–Positive Disease

Genomics/Genetics

Analysis Seeks to Identify Characteristics of 'Exceptional Responders' to Cancer Therapy

In a comprehensive analysis of patients with cancer who had exceptional responses to therapy, researchers identified molecular changes in the patients’ tumors that may explain some of these outcomes. The results, published by Wheeler et al in Cancer Cell, demonstrated that genomic characterizations ...

Breast Cancer
Survivorship
Issues in Oncology

Effect of Fertility Preservation on Reproductive Outcomes in Patients After Breast Cancer

In a Swedish nationwide cohort study reported in JAMA Oncology, Marklund et al found that women who had undergone fertility preservation had a higher live birth rate, were more likely to use assisted reproductive technology, and had better overall survival after breast cancer than women who had not ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Deintensifying Radiation Therapy

Lung Cancer

Adjuvant Irinotecan/Cisplatin vs Etoposide/Cisplatin for Resected High-Grade Neuroendocrine Carcinoma of the Lung

In a Japanese phase III trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant irinotecan/cisplatin did not improve relapse-free survival vs etoposide/cisplatin in patients with completely resected, pathologic stage I–IIIA, high-grade neuroendocrine carcinoma of the...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...